日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

ETV6-NTRK3 as a resistance mechanism to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: favorable response after combination of osimertinib and entrectinib: a case report and literature review

ETV6-NTRK3作为表皮生长因子受体(EGFR)酪氨酸激酶抑制剂的耐药机制:奥希替尼联合恩曲替尼治疗后疗效良好:病例报告及文献综述

Xie, Wei; Luo, Han; Wang, Huan; Shi, Guangqing; Tang, Jiajun; Ma, Lijie; Zhou, Jing

Adjuvant Larotrectinib in a Resected Secretory Carcinoma-Like Lung Adenocarcinoma Harboring EML4-NTRK3 Fusion: Case Report

辅助拉罗替尼治疗切除的伴有EML4-NTRK3融合基因的分泌性癌样肺腺癌:病例报告

Cordeiro de Lima, Vladmir Cláudio; Araújo, Breno Jeha; Costa, Felipe D' Almeida; Teixeira, Beatriz Fuga Rossi; Cicilini, André Luiz; Fernandes, Carolina de Bustamante; Morellato, Juliana Folador; Dienstmann, Rodrigo; Laloni, Mariana Tosello

Oncogenic NTRK3 mutations exhibit differential sensitivity to tropomyosin receptor kinase inhibitors in patients with acute myeloid leukemia

致癌性 NTRK3 突变在急性髓系白血病患者中对原肌球蛋白受体激酶抑制剂表现出不同的敏感性。

Joshi, Sunil K; Huang, Ariane; Pittsenbarger, Janét; Shinde, Ujwal; Posso, Camilo; Piehowski, Paul D; Gosline, Sara J C; Press, Richard D; Gritsenko, Marina A; Hutchinson, Chelsea; Weitz, Karl K; Watanabe-Smith, Kevin; Long, Nicola; Rodland, Karin D; Tyner, Jeffrey W; Druker, Brian J; Tognon, Cristina E

Case Report: Dramatic response to entritinib in a patient with gastrointestinal stromal tumor positive for NTRK3 fusion

病例报告:NTRK3融合基因阳性的胃肠道间质瘤患者对恩曲替尼治疗反应显著

Dong, Guomin; Han, Pengyu; Zhang, Zhiyun; Ge, Qian; Jiang, Jian; Li, Suoni; Ma, Jiequn; Bai, Jie; Wei, Hui; Zhao, Zheng

Primary pancreas NTRK-rearranged neoplasm harboring an EVT6::NTRK3 fusion with a sclerosing epithelioid fibrosarcoma morphology: a case report and comprehensive review of the literature

原发性胰腺NTRK重排肿瘤伴EVT6::NTRK3融合基因,并具有硬化性上皮样纤维肉瘤形态:病例报告及文献综述

Wu, Xin; Li, Dujuan; Fu, Fangfang; Lian, Lifei

A case of quadruple wild-type gastrointestinal stromal tumor with CDC42BPB::NTRK3 fusion and abundant lymphoid infiltration

一例四重野生型胃肠道间质瘤,伴有CDC42BPB::NTRK3融合基因和大量淋巴细胞浸润

Xiang, Wentao; Yuan, Wei; Ren, Lei; Huang, Wen; Liang, Huaiyu; Huang, Jie; Luan, Lijuan; Xu, Chen; Hou, Yingyong

On TRacK With Larotrectinib in a Neonate With a Giant Congenital ETV6::NTRK3 Fusion-Positive Infantile Fibrosarcoma of the Head and Neck

接受拉罗替尼治疗的新生儿巨大先天性ETV6::NTRK3融合阳性婴儿头颈部纤维肉瘤

Cardesa-Salzmann, Teresa M; Sparber-Sauer, Monika; Hingst, Peter; Erbersdobler, Andreas; Schneider, Bjoern; Hühns, Maja; Jakob, Andre; Terpe, Friederike; Spang, Christian; Stalmann, Dorothea; Bierwirth, Claudia; Hauenstein, Christina; Märzheuser, Stefanie; Ballmann, Manfred; Classen, Carl Friedrich

Rapidly Growing ALK-Negative NTRK3-Positive Inflammatory Myofibroblastic Tumour of the Lung

肺部快速生长的ALK阴性NTRK3阳性炎性肌纤维母细胞瘤

Sato, Yukitaka; Kojima, Fumitsugu; Ushigusa, Takeshi; Kabemura, Shinsaku; Jinta, Torahiko; Bando, Toru

A case of primary ovarian clear cell carcinoma with ETV6::NTRK3 fusion.

一例伴有ETV6::NTRK3融合的原发性卵巢透明细胞癌。

Ochiai Daisuke, Chiyoda Tatsuyuki, Nakamura Kohei, Takamatsu Reika, Jisaka Mitsuyo, Sakamaki Tomomi, Takahashi Mio, Kimura Yumiko, Oki Shinya, Yoshihama Tomoko, Sakai Kensuke, Nishihara Hiroshi, Yamagami Wataru

Extraskeletal osteosarcoma harboring ETV6::NTRK3 fusion treated successfully with larotrectinib: a case study

一例携带ETV6::NTRK3融合基因的骨外骨肉瘤经拉罗替尼成功治疗:病例报告

Skok, Kristijan; Ochsenhofer, Florian; Gassner, Raphael; Leithner, Andreas; Szkandera, Joanna; Viertler, Christian; Hasenschwandtner, Sonja; Reichinger, Andreas; Liegl-Atzwanger, Bernadette